Cargando…

Trends in Cost Attributable to Kidney Transplantation Evaluation and Waiting List Management in the United States, 2012-2017

IMPORTANCE: While recent policy reforms aim to improve access to kidney transplantation for patients with end-stage kidney disease, the cost implications of kidney waiting list expansion are not well understood. The Organ Acquisition Cost Center (OACC) is the mechanism by which Medicare reimburses k...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Xingxing S., Han, Jialin, Braggs-Gresham, Jennifer L., Held, Philip J., Busque, Stephan, Roberts, John P., Tan, Jane C., Scandling, John D., Chertow, Glenn M., Dor, Avi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914579/
https://www.ncbi.nlm.nih.gov/pubmed/35267033
http://dx.doi.org/10.1001/jamanetworkopen.2022.1847
_version_ 1784667745719156736
author Cheng, Xingxing S.
Han, Jialin
Braggs-Gresham, Jennifer L.
Held, Philip J.
Busque, Stephan
Roberts, John P.
Tan, Jane C.
Scandling, John D.
Chertow, Glenn M.
Dor, Avi
author_facet Cheng, Xingxing S.
Han, Jialin
Braggs-Gresham, Jennifer L.
Held, Philip J.
Busque, Stephan
Roberts, John P.
Tan, Jane C.
Scandling, John D.
Chertow, Glenn M.
Dor, Avi
author_sort Cheng, Xingxing S.
collection PubMed
description IMPORTANCE: While recent policy reforms aim to improve access to kidney transplantation for patients with end-stage kidney disease, the cost implications of kidney waiting list expansion are not well understood. The Organ Acquisition Cost Center (OACC) is the mechanism by which Medicare reimburses kidney transplantation programs, at cost, for costs attributable to kidney transplantation evaluation and waiting list management, but these costs have not been well described to date. OBJECTIVES: To describe temporal trends in mean OACC costs per kidney transplantation and to identify factors most associated with cost. DESIGN, SETTING, AND PARTICIPANTS: This economic evaluation included all kidney transplantation waiting list candidates and recipients in the United States from 2012 to 2017. A population-based study of cost center reports was conducted using data from all Center of Medicare & Medicaid–certified transplantation hospitals. Data analysis was conducted from June to August 2021. EXPOSURES: Year, local price index, transplantation and waiting list volume of transplantation program, and comorbidity burden. MAIN OUTCOMES AND MEASURES: Mean OACC costs per kidney transplantation. RESULTS: In 1335 hospital-years from 2012 through 2017, Medicare’s share of OACC costs increased from $0.95 billion in 2012 to $1.32 billion in 2017 (3.7% of total Medicare End-Stage Renal Disease program expenditure). Median (IQR) OACC costs per transplantation increased from $81 000 ($66 000 to $103 000) in 2012 to $100 000 ($82 000 to $125 000) in 2017. Kidney organ procurement costs contributed to 36% of mean OACC costs per transplantation throughout the study period. During the study period, transplantation hospitals experienced increases in kidney waiting list volume, kidney waiting list active volume, kidney transplantation volume, and comorbidity burden. For a median-sized transplantation program, mean OACC costs per transplantation decreased with more transplants (−$3500 [95% CI, −$4300 to −$2700] per 10 transplants; P < .001) and increased with year ($4400 [95% CI, $3500 to $5300] per year; P < .001), local price index ($1900 [95% CI, $200 to $3700] per 10-point increase; P = .03), patients listed active on the waiting list ($3100 [95% CI, $1700 to $4600] per 100 patients; P < .001), and patients on the waiting list with high comorbidities ($1500 [9% CI, $600 to $2500] per 1% increase in proportion of waitlisted patients with the highest comorbidity score; P = .002). CONCLUSIONS AND RELEVANCE: In this study, OACC costs increased at 4% per year from 2012 to 2017 and were not solely attributable to the cost of organ procurement. Expanding the waiting list will likely contribute to further increases in the mean OACC costs per transplantation and substantially increase Medicare liability.
format Online
Article
Text
id pubmed-8914579
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-89145792022-03-25 Trends in Cost Attributable to Kidney Transplantation Evaluation and Waiting List Management in the United States, 2012-2017 Cheng, Xingxing S. Han, Jialin Braggs-Gresham, Jennifer L. Held, Philip J. Busque, Stephan Roberts, John P. Tan, Jane C. Scandling, John D. Chertow, Glenn M. Dor, Avi JAMA Netw Open Original Investigation IMPORTANCE: While recent policy reforms aim to improve access to kidney transplantation for patients with end-stage kidney disease, the cost implications of kidney waiting list expansion are not well understood. The Organ Acquisition Cost Center (OACC) is the mechanism by which Medicare reimburses kidney transplantation programs, at cost, for costs attributable to kidney transplantation evaluation and waiting list management, but these costs have not been well described to date. OBJECTIVES: To describe temporal trends in mean OACC costs per kidney transplantation and to identify factors most associated with cost. DESIGN, SETTING, AND PARTICIPANTS: This economic evaluation included all kidney transplantation waiting list candidates and recipients in the United States from 2012 to 2017. A population-based study of cost center reports was conducted using data from all Center of Medicare & Medicaid–certified transplantation hospitals. Data analysis was conducted from June to August 2021. EXPOSURES: Year, local price index, transplantation and waiting list volume of transplantation program, and comorbidity burden. MAIN OUTCOMES AND MEASURES: Mean OACC costs per kidney transplantation. RESULTS: In 1335 hospital-years from 2012 through 2017, Medicare’s share of OACC costs increased from $0.95 billion in 2012 to $1.32 billion in 2017 (3.7% of total Medicare End-Stage Renal Disease program expenditure). Median (IQR) OACC costs per transplantation increased from $81 000 ($66 000 to $103 000) in 2012 to $100 000 ($82 000 to $125 000) in 2017. Kidney organ procurement costs contributed to 36% of mean OACC costs per transplantation throughout the study period. During the study period, transplantation hospitals experienced increases in kidney waiting list volume, kidney waiting list active volume, kidney transplantation volume, and comorbidity burden. For a median-sized transplantation program, mean OACC costs per transplantation decreased with more transplants (−$3500 [95% CI, −$4300 to −$2700] per 10 transplants; P < .001) and increased with year ($4400 [95% CI, $3500 to $5300] per year; P < .001), local price index ($1900 [95% CI, $200 to $3700] per 10-point increase; P = .03), patients listed active on the waiting list ($3100 [95% CI, $1700 to $4600] per 100 patients; P < .001), and patients on the waiting list with high comorbidities ($1500 [9% CI, $600 to $2500] per 1% increase in proportion of waitlisted patients with the highest comorbidity score; P = .002). CONCLUSIONS AND RELEVANCE: In this study, OACC costs increased at 4% per year from 2012 to 2017 and were not solely attributable to the cost of organ procurement. Expanding the waiting list will likely contribute to further increases in the mean OACC costs per transplantation and substantially increase Medicare liability. American Medical Association 2022-03-10 /pmc/articles/PMC8914579/ /pubmed/35267033 http://dx.doi.org/10.1001/jamanetworkopen.2022.1847 Text en Copyright 2022 Cheng XS et al. JAMA Network Open. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Cheng, Xingxing S.
Han, Jialin
Braggs-Gresham, Jennifer L.
Held, Philip J.
Busque, Stephan
Roberts, John P.
Tan, Jane C.
Scandling, John D.
Chertow, Glenn M.
Dor, Avi
Trends in Cost Attributable to Kidney Transplantation Evaluation and Waiting List Management in the United States, 2012-2017
title Trends in Cost Attributable to Kidney Transplantation Evaluation and Waiting List Management in the United States, 2012-2017
title_full Trends in Cost Attributable to Kidney Transplantation Evaluation and Waiting List Management in the United States, 2012-2017
title_fullStr Trends in Cost Attributable to Kidney Transplantation Evaluation and Waiting List Management in the United States, 2012-2017
title_full_unstemmed Trends in Cost Attributable to Kidney Transplantation Evaluation and Waiting List Management in the United States, 2012-2017
title_short Trends in Cost Attributable to Kidney Transplantation Evaluation and Waiting List Management in the United States, 2012-2017
title_sort trends in cost attributable to kidney transplantation evaluation and waiting list management in the united states, 2012-2017
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914579/
https://www.ncbi.nlm.nih.gov/pubmed/35267033
http://dx.doi.org/10.1001/jamanetworkopen.2022.1847
work_keys_str_mv AT chengxingxings trendsincostattributabletokidneytransplantationevaluationandwaitinglistmanagementintheunitedstates20122017
AT hanjialin trendsincostattributabletokidneytransplantationevaluationandwaitinglistmanagementintheunitedstates20122017
AT braggsgreshamjenniferl trendsincostattributabletokidneytransplantationevaluationandwaitinglistmanagementintheunitedstates20122017
AT heldphilipj trendsincostattributabletokidneytransplantationevaluationandwaitinglistmanagementintheunitedstates20122017
AT busquestephan trendsincostattributabletokidneytransplantationevaluationandwaitinglistmanagementintheunitedstates20122017
AT robertsjohnp trendsincostattributabletokidneytransplantationevaluationandwaitinglistmanagementintheunitedstates20122017
AT tanjanec trendsincostattributabletokidneytransplantationevaluationandwaitinglistmanagementintheunitedstates20122017
AT scandlingjohnd trendsincostattributabletokidneytransplantationevaluationandwaitinglistmanagementintheunitedstates20122017
AT chertowglennm trendsincostattributabletokidneytransplantationevaluationandwaitinglistmanagementintheunitedstates20122017
AT doravi trendsincostattributabletokidneytransplantationevaluationandwaitinglistmanagementintheunitedstates20122017